Canthera Discovery (CTx CRC Limited)

GlycoSyn is a business unit of Callaghan Innovation, and specialises in the production of process intermediates and Active Pharmaceutical Ingredients (APIs), including under GMP. GlycoSyn’s world-class expertise in carbohydrate chemistry and its GMP manufacturing facility are in New Zealand, near the capital city of Wellington. From here, the company partners with clients in all corners of the globe.

As small molecule specialists, GlycoSyn has built a distinguished track record in chemical and chemo-enzymatic synthesis. We have successfully applied this expertise to the development of enzyme inhibitors, dendrimer constructs, glycopolymers, and vaccine adjuvants in the treatment of cancers, rare diseases, and neurodegenerative diseases.

Our expertise in Carbohydrate Chemistry began in the 1980’s with Drs Furneaux, Ferrier and Tyler. The team now includes over 50 PhD Chemists and Analysts with substantial publication records and outputs, including 4 compounds in clinical development. This enormous reservoir of carbohydrate and complex chemistry expertise is what makes GlycoSyn unique as a CRO/CDMO. Thanks to our links with the Ferrier Research Institute and Callaghan Innovation, we have the largest combined concentration of carbohydrate chemistry and cGMP manufacturing expertise in the world.

Services

• Contract Discovery and Medicinal Chemistry
• Process Development & GMP manufacture
• APIs for Preclinical & Clinical Trials
• Analytical Development
(Method Qualification & Validation as appropriate)
• Metabolite Standards

GMP Manufacture

• Specialists in complex multi-step synthesis
 30 year track record
• cGMP manufacturing since 2003
• Licensed to manufacture medicines
(PIC/S GMP Pt II, ICH Q7 equivalent)

SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases.

There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors.

Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.

At Wesley Medical Research, we're making a difference today.

Our researchers are doctors, nurses, and other health professionals at UnitingCare Health hospitals throughout Queensland. They work directly with patients to immediately alleviate pain and suffering, making lasting improvements to health care practices for future generations.

Our research findings are applied in public and private healthcare facilities to improve health care practices, patient care and quality of life for everyone.

Biosensis specializes in antibodies and reagents for Neuroscience. Our
neuroscience portfolio includes products for research in neurodegenerative
diseases, neurodevelopment,and neuro-metabolism. Areas of focus include
Alzheimer's, Parkinson's and ALS diseases, as well as autophagy and
metabolic and stress disorders including metabolic syndrome research,
obesity, and neuroimmunology and inflammation with particular emphasis on
neurotrophins and neurotrophin receptors for which Biosensis has been the
worldwide leader and OEM supplier for more than 30 years.
Biosensis also offers more than 200 high-quality ELISA kits for a wide range
of protein targets. Our assays are validated for a variety of sample matrices and where possible, tested by independent research laboratories. Our ELISA kits are complete, ready-to-use and without the need for additional reagents, buffers or plates. Plus our strip format allows you to only use what you need! Our detailed protocols include extensive information about sample preparation, assay execution, data analysis and validation. Full technical support is also provided by our highly skilled technical team at biospeak@biosensis.com.

Our new range of RapidTM ELISA assays can be performed in less than 4 hours
without compromising on accuracy, specificity and sensitivity. These assays
target potential biomarkers, such as oligomeric Aβ peptides (Alzheimer's
Disease, AD), mature BDNF (psychiatric disorders), proNGF (cancer) and
p75NTR/NGFR (Amytrophic Lateral Sclerosis, ALS).
Why purchase from Biosensis?
Biosensis is a company formed by a team of life scientists and business
people dedicated to the support of researchers in academia and industry
worldwide. The team has a combined total of over 50 years experience in the
commercialization of life science reagents for the life science research and diagnostic markets. We are therefore able to offer a level of customer support and expertise unmatched in the neuroscience reagent industry.

Children’s Medical Research Institute (CMRI) pioneered microsurgery, immunisations against lethal childhood illnesses, and care for premature babies, all of which has improved the lives of countless Australian children.

The work at CMRI is made possible by a network of devoted community supporters and Jeans for Genes®, the iconic fundraising campaign established in 1994 to fund revolutionary research that helps diagnose, understand, and find cures or treatments for conditions affecting kids.

Today, CMRI is an independent institute and the site of world-leading research in the areas of cancer, neurobiology, embryology, proteogenomics and gene therapy. CMRI is affiliated with the University of Sydney and is a founding partner of Paediatrio and the Westmead Research Hub.

CMRI collaborates with scientists all over the world to push research forward. It also provides important resources for scientists in Australia. It operates CellBank Australia™, the only national repository of cell cultures in Australia, necessary for many fields of medical science; as well as advanced gene therapy and gene engineering facilities--creating treatments of the future. In addition, CMRI houses the ACRF Cancer Centre, which includes the ACRF Centre for Kinomics, ACRF Telomere Analysis Centre and ACRF ProCan®, whose combined efforts are to understand, improve diagnosis, survivability and discover new treatments for all types of cancer.